目的 研究普伐他汀钠片联合酒石酸美托洛尔片治疗冠心病心力衰竭的临床疗效。方法 选取2015年10月—2017年10月成都军区总医院接收的冠心病心力衰竭患者120例为研究对象，将所有患者随机分为对照组和治疗组，每组各60例。对照组口服酒石酸美托洛尔片，2片/次，2次/d。治疗组在对照组治疗的基础上口服普伐他汀钠片，1片/次，1次/d。两组患者均持续治疗3个月。观察两组的临床疗效，比较两组的心功能指标和血清炎症因子水平。结果 治疗后，对照组和治疗组的总有效率分别为78.33%、96.67%，两组比较差异有统计学意义（P<0.05）。治疗后，两组左室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）明显下降，左心射血分数（LVEF）明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组心功能指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清肿瘤坏死因子-α（TNF-α）、脑钠肽（BNP）和超敏C反应蛋白（hs-CRP）水平均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清炎症因子水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 普伐他汀钠片联合酒石酸美托洛尔片治疗冠心病心力衰竭具有较好的临床疗效，可改善心功能指标，调节炎性因子水平，安全性较好，具有一定的临床推广应用价值。

Objective To study the clinical effect of Pravastatin Sodium Tablets combined with Metoprolol Tartrate Tablets in treatment of heart failure of coronary heart disease. Methods Patients (120 cases) with heart failure of coronary heart disease in Chengdu Military General Hospital from October 2015 to October 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Metoprolol Tartrate Tablets, 2 tablets/time, twice daily. Patients in the treatment group were po administered with Pravastatin Sodium Tablets on the basis of the control group, 1 tablet/time, once daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and cardiac function indexes and serum cytokine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.33% and 96.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVESD and LVEDD in two groups were significantly decreased, but LVEF in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TNF-α, BNP, and hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serum cytokine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Pravastatin Sodium Tablets combined with Metoprolol Tartrate Tablets has clinical curative effect in treatment of heart failure of coronary heart disease, can improve cardiac function indexes, and regulate serum cytokine levels, with good safety, which has a certain clinical application value.